Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Phase 1 | US | 01 Dec 2026 |